Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a single arm study, conducted at two centers, of neoadjuvant sotorasib in treatment
naïve patients with stage Ib-IIIa NSCLC. The study will accrue 25 patients in all. Patients
must have been deemed surgically resectable and physiologically fit for surgery by a thoracic
surgeon prior to enrollment.